BLASUBCUTANEOUSVIAL
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Interleukin 1 Receptor Antagonists
Pharmacologic Class:
Interleukin-1 Receptor Antagonist
Clinical Trials (5)
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
Started Sep 2025
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
Started Oct 2023
A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
Started Dec 2022
52 enrolled
Cystic Fibrosis, 10011762
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Started Aug 2022
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Started Dec 2021